戻る
Lyell Immunopharma Inc (LYEL)価格
LYEL 株価推移チャート
LYEL 収入
Lyell Immunopharma Inc
$21.05
-0.37%
$-0.07
終値： Mar 16, 16:00:00 GMT-4
$21.05
0%
$0
プレマーケット： Mar 17, 10:14:24 GMT-4
主要データ
前終値
$21.13
始値
$21.15
当日レンジ
$20.88 - $21.96
52週レンジ
$7.65 - $45
取引高
11.5K
平均取引高
115.9K
1株当たり利益(TTM)
-22.26
配当利回り
--
時価総額
$447.1M
LYELとは何ですか？
Lyell Immunopharma, Inc. operates as a holding company, which engages in the development of cell-based immunotherapies for human diseases. The company is headquartered in South San Francisco, California and currently employs 300 full-time employees. The company went IPO on 2021-06-17. The Company’s product candidates include LYL314 and LYL273. Its LYL314, which is in Phase I/II clinical development, is a dual-targeting CD19/CD20 CAR T-cell product candidate designed to increase complete response rates and prolong the duration of response as compared to the approved CD19-targeted CAR T-cell therapies and is under evaluation trial for the treatment of patients with relapsed and/or refractory large B-cell lymphoma. The firm has acquired the global rights to LYL273 (formerly GCC19CART), a novel autologous guanylyl cyclase-C (GCC)-targeted CAR T-cell product candidate for the treatment of metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.